Please login to the form below

Not currently logged in
Email:
Password:

Sandoz targets digital therapeutics

Partners with Pear Therapeutics to launch FDA-approved apps

Sandoz

Novartis’ generics and biosimilar division Sandoz has partnered with Pear Therapeutics to commercialise two mobile phone applications, reSET and reSET-O.

reSET, an app that treats patients with substance abuse disorder (SUD), was cleared for use by the US Food and Drug Administration (FDA) last year, an approval which saw the app become the first prescription-based, digital therapeutic that claims to progress clinical outcomes in a disease.

It’s second app known as reSET-O, which is currently under review by the FDA, has potential in treating people with opioid use disorder (OUD) and was granted an expedited access pathway designation last October.

Corey McCann, president and chief executive officer of Pear Therapeutics, said: “After a competitive evaluation process among potential partners, Sandoz emerged as the best fit to commercialise reSET and reSET-O.

“Sandoz has a demonstrated record of successful commercial execution both in the US and globally, has extensive expertise working with clinicians and patients, and will provide a dedicated sales force to market both reSET and reSET-O.”

As per terms of the deal, the Novartis subsidiary will assume responsibility for the global commercial launch of the apps, including market access developments, ensuring reimbursement from payers and providing a sales force.

In addition to an upfront payment, the deal includes research and development funding, commercial milestones and a profit split on net sales of both apps.

Pear, on the other hand, will continue to develop both digital therapeutics and will also support patient services through its digital hub service.

This is the second time Novartis has collaborated with Pear Therapeutics, following its initial deal covering the development of a range of prescription software apps that can be used to treat patients suffering with schizophrenia and multiple sclerosis.

Article by
Gemma Jones

30th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics